X-linked Opitz syndrome (XLOS), caused by mutation in the MID1 gene, is a midline malformation syndrome with obvious craniofacial abnormalities. Because cranial neural crest cells (CNC) play a pivotal role in cranial morphogenesis, we examined the spatio-temporal expression of cMid1 in chick embryos and investigated if alterations in Mid1 protein function, specifically the ability of Mid1 to negatively regulate levels of protein phosphatase 2A (PP2A), affected CNC survival or migration. During the main phase of CNC migration (stage 9 to 11) cMid1 is strongly expressed within r2 and a subset of CNC in cranial mesenchyme at the level of r1/2 to the isthmus, but is not expressed in more caudal CNC streams. Inhibiting cMid1 function in r2 elevated PP2A levels. Overexpression of PP2A in r2 slowed CNC migration in vitro and in ovo and inhibited trigeminal gangliogenesis. Conversely in r4, forced expression of cMid1, or pharmacological inhibition of PP2A lowered PP2A levels. Inhibition of PP2A in r4 CNC in vitro up-regulated the disintegrin and metalloprotease ADAM10 and selectively increased CNC motility on fibronectin and collagen substrates, but not on laminin. In ovo, inhibiting PP2A activity in r4 increased CNC migration and hastened formation of the geniculate/vestibuloacoustic ganglion, comprising mostly epibranchial placode neuroblasts. Placodal neuroblast migration into the cranial mesenchyme is known to depend on the presence of r4 CNC and we show that inhibition of PP2A in r4 CNC causes premature breakdown of the epibranchial placode basement membrane and early immigration of placodal neuroblasts. In all cases, CNC proliferation and death were unaffected by altered PP2A levels. We propose that factors capable of altering PP2A activity, such as Mid1, affect CNC motility and matrix remodeling, thereby modulating craniofacial development.

No abstract

COVID-19 has forced rapid clinical translation of novel vaccine technologies, principally mRNA vaccines, that have resulted in meaningful efficacy and adequate safety in response to the global pandemic. Notwithstanding this success, there remains an opportunity for innovation in vaccine technology to address current limitations and meet the challenges of inevitable future pandemics. We describe a universal vaccine cell (UVC) rationally designed to mimic the natural physiologic immunity induced post viral infection of host cells. Induced pluripotent stem cells were CRISPR engineered to delete MHC-I expression and simultaneously overexpress a NK Ligand adjuvant to increase rapid cellular apoptosis which was hypothesized to enhance viral antigen presentation in the resulting immune microenvironment leading to a protective immune response. Cells were further engineered to express the parental variant WA1/2020 SARS-CoV-2 spike protein as a representative viral antigen prior to irradiation and cryopreservation. The cellular vaccine was then used to immunize non-human primates in a standard 2-dose, IM injected prime + boost vaccination with 1e8 cells per 1 ml dose resulting in robust neutralizing antibody responses (1e3 nAb titers) with decreasing levels at 6 months duration. Similar titers generated in this established NHP model have translated into protective human neutralizing antibody levels in SARS-Cov-2 vaccinated individuals. Animals vaccinated with WA1/2020 spike antigens were subsequently challenged with 1.0 x 105 TCID50 infectious Delta (B.1.617.2) SARS-CoV-2 in a heterologous challenge which resulted in an approximately 3-log order decrease in viral RNA load in the lungs. These heterologous viral challenge results reflect the ongoing real-world experience of original variant WA1/2020 spike antigen vaccinated populations exposed to rapidly emerging variants like Delta and now Omicron. This cellular vaccine is designed to be a rapidly scalable cell line with a modular poly-antigenic payload to allow for practical, large-scale clinical manufacturing and use in an evolving viral variant environment. Human clinical translation of the UVC is being actively explored for this and potential future pandemics.